Globus Medical Q2 2026 Earnings: Margin Expansion Lifts Adjusted EPS

Globus Medical (NYSE: GMED) reported Q2 2026 net sales of $789.6 million, up 5.9% year over year, while GAAP diluted EPS fell 26.2% to $1.10 from $1.49. Underlying profitability moved in the opposite direction: non-GAAP diluted EPS increased 55.8%, adjusted EBITDA margin expanded, and quarterly free cash flow reached $176.6 million.

Core financial results

Revenue growth was accompanied by lower cost of sales and lower operating expenses in several categories. That combination lifted GAAP gross margin to 66.8% and more than doubled operating income, while adjusted EBITDA margin increased by 740 basis points to 35.4%.

The decline in GAAP net income did not reflect weaker operations. The prior-year quarter included a $110.5 million bargain-purchase gain associated with the Nevro acquisition, as well as an income tax benefit, making the GAAP comparison unusually difficult.

Business and segment performance

Musculoskeletal Solutions remained the growth engine, with sales rising approximately 7.5% to $763.5 million. Enabling Technologies moved in the opposite direction, declining approximately 25.8% to $26.1 million from $35.2 million.

Geographically, U.S. sales increased 3.0% to $619.1 million, while international sales rose 18.0% to $170.5 million, or 16.2% in constant currency. Management highlighted 7% growth in U.S. Spine and 14% reported growth in International Spine, including 12% constant-currency growth.

Management also said revenue grew 9% when Nevro was excluded, compared with reported companywide growth of 5.9%. This indicates that the underlying businesses grew faster than the consolidated result including the acquired operation.

Profitability, cash flow, and the balance sheet

Adjusted gross margin increased 200 basis points to 69.4%. On a GAAP basis, cost of sales declined to $241.4 million despite higher revenue. Selling, general and administrative expense also fell to $286.8 million from $303.6 million, while acquisition-related and restructuring expenses were lower than a year earlier. These changes explain the sharp increase in operating income and adjusted earnings.

Quarterly operating cash flow rose to $209.7 million from $77.9 million. After $33.2 million of property and equipment purchases, free cash flow was $176.6 million, compared with $31.3 million in the prior-year quarter.

At June 30, Globus Medical held $840.5 million of cash, cash equivalents, and marketable securities, up from $629.1 million at the end of 2025. Cash alone decreased slightly to $507.7 million as the company increased its holdings of marketable securities. Inventory rose to $810.9 million from $759.3 million and used $44.6 million of cash during the first six months of 2026.

Prior-year Nevro gain masks underlying earnings improvement

The central earnings issue is the divergence between GAAP net income and operating performance. Operating income increased to $182.4 million, but GAAP net income declined because Q2 2025 contained the $110.5 million Nevro bargain-purchase gain and a $14.7 million income tax benefit. Q2 2026 instead included a $38.2 million tax provision.

After excluding acquisition-related items, intangible amortization, restructuring costs, and other specified adjustments, non-GAAP net income rose approximately 57.8% to $184.3 million. The corresponding 55.8% increase in non-GAAP EPS therefore provides a more favorable comparison than reported GAAP EPS, although the excluded costs remain relevant when evaluating total profitability.

Full-year guidance

Globus Medical reaffirmed its 2026 revenue range but raised non-GAAP diluted EPS guidance by $0.25 at both ends. With the sales outlook unchanged, the revision is centered on expected profitability rather than higher revenue, consistent with management’s focus on margin expansion, operating leverage, and acquisition synergies.

The company did not provide a quantitative reconciliation from expected GAAP EPS to non-GAAP EPS because the timing and size of the relevant adjustments cannot be predicted with reasonable certainty.

Recent insider transactions

The supplied six-month insider summary reports 82,500 shares purchased across five transactions and 55,000 shares sold across three transactions, resulting in net purchases of 27,500 shares. It lists total insider holdings of approximately 985,510 shares and net purchases equal to 2.90% of those holdings. These figures describe the reported transactions but do not establish insiders’ views on valuation or future performance.

The ten most recent individual records supplied are shown below; all were classified as direct ownership transactions.

Risks investors should monitor

• Enabling Technologies weakness: Sales in this category fell approximately 25.8%, contrasting with growth in Musculoskeletal Solutions. A continued decline would weigh on product diversification and total revenue growth.
• Dependence on margin execution: Revenue guidance was unchanged while non-GAAP EPS guidance increased. Delivering the higher earnings range therefore depends on continued gross-margin improvement, operating leverage, and synergy realization.
• Nevro integration and adjusted-cost exclusions: Companywide growth remained below growth excluding Nevro, while non-GAAP results continued to exclude acquisition-related, restructuring, and intangible amortization expenses.
• Inventory and working-capital requirements: Inventory increased by $51.6 million from year-end and consumed $44.6 million of cash during the first half. Further accumulation could reduce cash conversion if sales do not absorb it.

Summary

Globus Medical’s Q2 2026 results combined moderate revenue growth with substantial operating-margin and cash-flow improvement. Spine growth, lower operating costs, and acquisition synergies supported higher adjusted earnings, while the prior-year Nevro bargain-purchase gain caused reported GAAP net income and EPS to decline. The main issues ahead are whether the company can sustain margin gains, improve the contribution from Nevro and Enabling Technologies, and convert its unchanged revenue outlook into the higher non-GAAP EPS range.